摘要
应用ＪＳＢ－１单克隆抗体（单抗），采用间接免疫荧光法对１０３例初诊急性髓细胞白血病（ＡＭＬ）患者ｍｄｒ１基因表达产物ｐ－１７０进行检测，发现ｐ－１７０表达率为２６％；ＡＭＬ亚型中以Ｍ＿５的ｐ－１７０表达率最高；ｐ－１７０表达与化疗反应及预后高度相关。同时应用一组相关单抗，采用同样方法分析了其中６７例患者细胞免疫标记与ｐ－１７０表达及预后的关系。结果显示：ＣＤ＿（１４）或ＣＤ＿（３４）表达与ｐ－１７０表达及预后高度相关；ＣＤ＿（１４）或ＣＤ＿（３４）与ｐ－１７０协同表达者更难获得ＣＲ，预后更差。提示在进行ｐ－１７０表达检测的同时，观察相关免疫标记的表达情况并进行综合分析，可能对预测化疗疗效及判断预后更有意义。
one marrow samples from 103 cases of acute non-lymphoblastic leukemia (ANLL) were analysed for theirmdrl gene expression and its relation io immunopheno-type and FAB subtype. A panel of monoclonal antibod-ies identifying P-170 and differentiation-associated anti-gens (CD7 , CD9 , CD13, , CD14 , CD15 , CD33 , CD34 , CD38,CD39 ,and JSB-1) were used for immunofluorescence as-say. The results showed that :①27 cases (26%) were P-170 pnsitive, with the highest incidence in M_5 (P<0. 01) , and this positivity showed significant correlationwith CD14 and CD34(P<0.01) ②Patients with any ofthe 3 markers mentioned above positive had poor prog-nosis with a significant low cornplete remission (CR)rate (P<0.01) ③Patients with P-170￣+/CD or P-170￣+/CD had even much poorer prognosis.
出处
《中华血液学杂志》
CSCD
北大核心
1995年第5期238-240,共3页
Chinese Journal of Hematology
基金
国家八.五攻关课题基金
关键词
白血病
髓细胞性
免疫分型
单克隆抗体
Acute non-lymphoblastic leukemiaMultidrug resistance P-glycoproteinlmmunophenotype Monoclonalantibody
